



Klaus Schollmeier, PhD

Chairman of the Board of Directors

Klaus Schollmeier became Chairman in October 2011 after having served as Chief Executive Officer of Santhera since 2004. Mr Schollmeier joined Graffinity Pharmaceuticals AG as CEO in 2003 and became CEO of the Company when Graffinity and MyoContract AG were combined to form Santhera in 2004. Prior to joining the biotechnology industry in 2003, he served as managing director of the health-care/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF's central laboratories in Ludwigshafen, Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, US (1989 to 1993). His business functions included general manager of BASF Pharma Netherlands from 1996 to 1998 and vice president and general manager for Western Europe thereafter. From 1994 to 1995, he led BASF's acquisition and integration of Boots Pharmaceuticals. Mr Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and in 1991, he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.